Bidirectional peripheral neural interface — product research program

Preserved source identity

Source PDF: output/pdf/novel-biotech-bpni-product-research-program-2026-08-12.pdfPrivate repository source

SHA-256: 36c8faa666ceb7d39d9f61ed49f9e4099d7d5e7deab1f23a4c5bd5e0b3046a43

A hash establishes byte identity, not truth or present authority. All ten pages were rendered and inspected. On source page 8, the first letter of “Two” is visibly clipped at the left page edge; the complete heading remains present in the PDF text layer and is transcribed here.

Source page 1 of 10 · executive summary

Accepted control package; no product selected

The source said the program had an accepted evidence baseline, layered functional model, neutral architecture frame, 28-question backlog, and gated roadmap through mid-June 2027.

Direction preserved

Direct peripheral-nerve forward path plus afferent return path; not reduced to prosthesis motion control.

Evidence bounded

Short human components exist; chronic exact-route direct ENG plus stimulation remains open.

Options stay neutral

Electronic, biohybrid, and combined families remain research branches with zero selected.

Next gate is not a device

Science must define a dimensionless simulator contract, then Backend must review it.

Source page 2 of 10 · system model

The layered idea becomes a chain of distinct claims

Forward path: central nervous system → peripheral nerve → recording interface → computer

1. Sense: candidate activity.
2. Confirm: existence / validity within a bound.
3. Reject artifact: keep unresolved state.
4. Condition: preserve provenance.
5. Classify: uncertainty retained.
6. Compute: propose; never authorize.

Return path: computer → stimulation interface → afferent peripheral nerve → central nervous system

1. Encode: bounded return content.
2. Command: proposal only.
3. Authorize: allow / inhibit / review.
4. Condition: no waveform or values.
5. Stimulate: delivery state.
6. Acknowledge / effect: report; do not infer benefit.

Source page 3 of 10 · evidence control

The accepted Science packet contains 34 bounded claims

QA PASS ≠ claim PASS.

Core boundary

B00 supplied N=2 component evidence over 4–5 weeks. Only S3 completed the limited closed-loop task: mixed neural + EMG median-USEA decode, separate ulnar-USEA stimulation, 41/47 trials, possible proprioception/efference-copy contribution, and exact timing unknown.

OPEN — chronic exact-route human system

No accepted record established chronic fully implanted direct natural ENG plus peripheral-nerve stimulation in one human platform.

UNKNOWN — same-interface duplex timing

Separate, alternating, same-session, time-interleaved, and simultaneous duplex were distinct claims.

FAIL — broad platform claims

Universality, broad novelty, feasibility, safety, efficacy, readiness, freedom to operate, and availability were not established or were prohibited at this breadth.

Source page 4 of 10 · problem landscape

Seven problem classes were narrowed — none became a product indication

The source warned that its bar lengths were visual routing emphasis only — not evidence scores, effect sizes, or rankings.

• 5 deferred: retained only as bounded questions or comparators; evidence prerequisites remained open.
• 1 research branch kept: motor loss survived for comparator narrowing only; not indication, architecture, or product selection.
• 1 rejected for now: diagnostics was a reversible prerequisite-gap disposition and did not fire KILL-04.

Invasive comparator rule: if a removable, temporary, usual-care, or lower-risk external system provides essentially the same bounded benefit, the invasive branch must stop or be reframed.

Source page 5 of 10 · architecture research

Three families remain neutral, unselected, and evidence-asymmetric

Only presently defensible common “platform” layer: schemas, provenance, uncertainty, calibration lifecycle, monitoring, and imported fail-closed semantics.

No common biological map, return code, anatomy, endpoint, or universal calibration followed.

Source page 6 of 10 · research roadmap

Eight dependency-ordered phases lead to a research closeout — not a launch

Can proceed now

Maintain the six research-control artifacts, questions, traceability, and exact Science imports.

Waiting

Branch-specific Science, dimensionless simulator contract, Backend review, and governance imports.

Blocked

Architecture or indication selection, simulator implementation, device visual, testing, fabrication, implantation, development.

Source page 7 of 10 · question backlog

Twenty-eight questions convert ambition into falsifiable decision points

Priority composition: P0 / evidence and problem gates — 10; P1 / discriminators and lifecycle — 10; P2 / program and artifact readiness — 8.

Kill / pivot discipline

• Missing evidence remains OPEN or UNKNOWN.
• Only Science defines or fires scientific thresholds.
• Killing one bounded branch does not kill all branches.
• Equivalent lower-risk benefit rejects the invasive branch.
• No family advances on aesthetic appeal or “living” status.
• KILL-04 remains prospective and unfired.

Question → evidence: named owner, dependency, required source record, route, population, duration, endpoint, and limitations. Evidence → decision: one bounded downstream decision, with uncertainty preserved and no claim upgrade. Decision → stop / pivot: a conditional routing consequence tied to accepted criteria — never elapsed time.

Source page 8 of 10 · gate control

Two gates are closed. Nine still prevent selection or visualization.

Science

Claims, comparators, routes, failure modes, kill criteria, simulator assumptions.

Backend

Runtime, technical security, offline/non-actuating behavior, monitoring, fail-closed execution.

Legal / Ethics / Regulatory

Privacy, consent, ethics, access/equity, coercive use, reversibility, regulatory and freedom-to-operate judgments.

Integrator + user

Later bounded research routing and exact visual authorization — never scientific truth by preference.

Visualization remains blocked. Report diagrams explain accepted records. They are not a device concept, architecture depiction, implant, blueprint, or G10 bypass.

Source page 9 of 10 · dormant blueprint program

Twelve explanatory candidates exist only as a gate plan

Every future exact artifact needs: prerequisite-owner acceptance → Independent QA reproduction → Integrator + user authorization → bounded nonfunctional production → final QA.

Product cannot self-authorize.

Source page 10 of 10 · custody & next action

The accepted program is reproducible, bounded, and ready for the next research gate

Independent QA: P0 / P1 / P2 / P3 = 0 / 0 / 0 / 0. Product QA turn 019ff63b-18d2-73a2-8009-5a80ca8dd8e1 reproduced all six hashes and made no writes.

Overall: REVISION. Release, product development, visualization, testing, and external action remained unauthorized.

1. Science simulator contract. Versioned, dimensionless assumptions, parameters, sources, and thresholds. Separate G0/G1 closure required.
2. Backend review. Only after Science acceptance: offline, non-actuating, runtime security, monitoring, and fail-closed requirements.
3. Research branch decision. Integrator + user decide one bounded problem or multiple branches. This remains research routing, not product selection.

Caveat preserved from the source: this report summarized accepted repository records. It was not clinical, regulatory, legal, safety, efficacy, novelty, patent, freedom-to-operate, feasibility, or development advice. No human testing, biological work, implant development, or availability was represented.